Peyrot M., Rubin RR, Lauritzen T., et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673-2679.
2.
UK Prospective Diabetes Study (UKPDS) Group.Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998 ;352:837-854.
3.
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study . BMJ.2000; 321:405-412.
4.
UK Prospective Diabetes Study (UKPDS) Group.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ.1998;317:703-713.
5.
Gaede P., Vedel P., Larsen N., Jensen GV, Parving HH, Pedersen O.Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med.2003;348:383-393.
6.
Donnan PT, MacDonald TM, Morris ADAdherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med.2002;19:279-284.
7.
Paes AH, Bakker A., Soe-Agnie CJImpact of dosage frequency on patient compliance. Diabetes Care. 1997;20:1512-1517.
8.
Polonsky WH, Fisher L., Guzman S., Villa-Caballero L., Edelman SVPsychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28:2543-2545.
Skovlund SE , van der Ven N., Pouwer F., Snoek F.Appraisal of insulin treatment in type 2 diabetes patients with and without previous experience of insulin therapy [abstract] . Diabetes.2003:52:A419.
11.
Polonsky WH , Jackson RAWhat's so tough about taking insulin? Addressing the problem of psychological insulin resistance in type 2 diabetes. Clin Diabetes. 2004;22:147-150.
12.
Brown JB, Nichols GA, Perry A.The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27:1535-1540.
13.
Riddle MCTimely addition of insulin to oral therapy for type 2 diabetes. Diabetes Care. 2002;25:395-396.
14.
Haque M., Emerson SH, Dennison CR, Navsa M., Levitt NSBarriers to initiating insulin therapy in patients with type 2 diabetes in public-sector primary health care centres in Cape Town. S Afr Med J.2005;95:798-802.
15.
Funnell MM, Kruger DF, Spencer M.Self-management support for insulin therapy in type 2 diabetes. Diabetes Educ. 2004;30: 274-280.
16.
Riddle MC, Rosenstock J., Gerich J.The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care . 2003;26:3080-3086.
17.
Rosenstock J., Sugimoto D., Strange P., Stewart JA, Soltes-Rak E., Dailey G.Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care. 2006;29:554-559.
18.
Halter JB, Kennedy L., Herman WH, Miller MFGlycemic control and safety of insulin glargine (GLAR) in elderly patients with type 2 diabetes mellitus (T2DM): the GOAL A1C Study. Abstracts of the 66th Scientific Sessions of the ADA. Diabetes. 2006;55(suppl 1):A114. Abstract 480-P.
19.
Zarate R., Agras WSPsychosocial treatment of phobia and panic disorders. Psychiatry . 1994;57:133-141.
